Pharmaceutical company touts 'breakthrough' cancer treatment


Patients participating in a trial for a new lung cancer treatment have shown signs of improved health, leading the pharmaceutical company behind the study to hail a major "breakthrough” in the field.

>> Read more trending news

The American company Bristol-Myers Squibb reported Monday that lung cancer patients treated with a combination of its anti-tumor drug Opdivo and its melanoma drug Yervoy showed encouraging results.

According to the company, the treatment fared better than chemotherapy for individuals with "first-line advanced non-small cell lung cancer," known as NSCLC.

>> Related: Just one drink a day can increase your risk of cancer, study warns

"This Phase 3 study shows superior PFS (progression-free survival) with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB (tumor mutation burden)," Dr. Matthew D. Hellmann, study investigator and medical oncologist at Memorial Sloan Kettering Cancer Center, said in a press release.

Dr. Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb, said that his company sees the results as "a breakthrough in cancer research and a meaningful step forward in determining which first-line lung cancer patients may benefit most from the combination of Opdivo and Yervoy."

>> On AJC.com: 7 surprising things that can increase your risk of cancer

"These findings attest to our deep understanding of cancer biology, leading translational medicine capabilities and commitment to developing new approaches for cancer patients," he added.

The treatment trials are currently in their final phase, meaning the next step is to seek approval from the Food and Drug Administration to market the drug combination as a treatment for this specific condition. A panel of experts formed to assess the data recommended that the clinical trial move forward, despite some modifications made during the trial, according to the company.

>> Related: New cancer 'vaccine' completely wipes out tumors in mice -- human trials are on way

Bristol-Myers Squibb has been a pioneer in immunotherapy, according to Reuters. But some analysts are still holding out to see whether or not the treatment will be a success.

"Overall survival is what matters," BMO Capital Markets analyst Alex Arfaei said, explaining that regulators prefer that standard.

"The survival benefit may not be that great," he added, pointing to other new promising treatments.

One analyst called the study "a clear win" for the company, but another cautioned that the report is "positive but unquantified data," according to Bloomberg.

Critics questioned whether the pharmaceutical company’s clinical trial design change may have sullied the results.

>> Related: Long-term aspirin users at lower risk of cancer, study concludes

According to MarketWatch, researchers made changes to the Phase 3 trial, called CheckMate-227, while it was already ongoing.

Bristol-Myers management addressed the concerns Monday in a conference call, stating that it responded to emerging science and only made changes after conversations with the Food and Drug Administration.

Nonetheless, the company is hailing the trials as "a true example" of "innovation."

>> On AJC.com: ‘One-stop’ blood test to detect cancer shows promise, scientists say

Overall survival data from the Opdivo and Yervoy combination trial will be released near the end of 2018 or early in 2019 the company said.

Already, Opdivo is the company's best-selling drug, reporting sales of $4.95 billion globally last year.

"By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers," Bristol-Myers Squibb explained.

>> Related: 72 major genetic risk factors for breast cancer identified in new study

The new trials will likely increase the drug's profitability as they further demonstrate its benefits, the company said. However, Seamus Fernandez, an analyst at Leerink Partners, pointed out that it remains to be seen whether combining Opdivo with Yervoy provides better results than taking the drug alone.

For now, Bristol-Myers Squibb is thanking the patients who participated in the trial leading to the "breakthrough."

"We would like to thank the patients and researchers who participated in these clinical trials — without whom this scientific advance would not be realized," the company said in a statement.


Reader Comments ...


Next Up in Nation World

Feds: Hamilton men scammed local Sam’s Clubs out of $50K of rewards points
Feds: Hamilton men scammed local Sam’s Clubs out of $50K of rewards points

Two Hamilton men with the same last name have been charged with scamming southwest Ohio Sam’s Club stores out of more than $50,000 worth of fraudulently acquired cash rewards points. Joshua C. Leavell, 25, and Cabel D. Leavell III, 59, also have been accused of generating more than 750 fraudulently refunded AutoZone gift cards. RELATED: Grand...
Retired Centerville police chief focus of investigation
Retired Centerville police chief focus of investigation

Centerville police chief Bruce Robertson’s recent retirement came amid an ongoing investigation into allegations of criminal conduct, according to city manager Wayne Davis. “There were allegations of criminal conduct, therefore we’re following up with conducting an internal investigation into those allegations,” Davis said in...
Olympian Gus Kenworthy rescues puppy from Korean dog meat farm
Olympian Gus Kenworthy rescues puppy from Korean dog meat farm

After rescuing dogs at the 2014 Sochi Winter Olympics, freestyle skier Gus Kenworthy has rescued another puppy. People reported that Kenworthy announced he and his boyfriend, actor Matthew Wilkas, rescued a puppy named Beemo. The Associated Press reported that the two visited visited a dog farm in Siheung, South Korea, Friday. >> Read more...
Kentucky bill would terminate parental rights of babies born to drug-addicted mothers
Kentucky bill would terminate parental rights of babies born to drug-addicted mothers

The opioid epidemic in the U.S. has claimed millions of victims and has spread into even remote corners of American society.  >> Read more trending news  While critics have accused states and the federal government of being slow to act in addressing the crisis, there has been a recent spotlight on the pharmaceutical companies&rsquo...
Weekend rain brings more flooding worries, could topple trees
Weekend rain brings more flooding worries, could topple trees

Widespread showers Saturday possibly laden with thunderstorms Saturday night will add to the region’s flooding risk and push already swollen local rivers to a crest on Sunday – all adding to woes south along the Ohio River. A National Weather Service flood watch extends until 10 a.m. Sunday in Butler, Clark, Greene, Montgomery, Preble and...
More Stories